Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin

John J. Kavanagh, Katherine Y. Yeung, Niramol Savaraj, Irwin H. Krakoff

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Thirteen patients were treated with both the oral and intravenous preparations of 4-demethoxydaunorubicin (DMDR). The drug was well tolerated in both forms. Neutropenia was the dose-limiting side-effect. Approximately 30% of the compound was absorbed when given orally. The maximum tolerated dose was 12.5 mg/m2 intravenously or 50 mg/m2 (10 mg/m2 q d × 5) orally, given every 21-28 days.

Original languageEnglish
Pages (from-to)1187-1189
Number of pages3
JournalEuropean Journal of Cancer and Clinical Oncology
Volume21
Issue number10
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Idarubicin
Maximum Tolerated Dose
Neutropenia
Pharmaceutical Preparations
compound 30

ASJC Scopus subject areas

  • Oncology

Cite this

Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin. / Kavanagh, John J.; Yeung, Katherine Y.; Savaraj, Niramol; Krakoff, Irwin H.

In: European Journal of Cancer and Clinical Oncology, Vol. 21, No. 10, 01.01.1985, p. 1187-1189.

Research output: Contribution to journalArticle

Kavanagh, John J. ; Yeung, Katherine Y. ; Savaraj, Niramol ; Krakoff, Irwin H. / Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin. In: European Journal of Cancer and Clinical Oncology. 1985 ; Vol. 21, No. 10. pp. 1187-1189.
@article{6cf48ad6d7464d37846aa2e5bc8500b6,
title = "Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin",
abstract = "Thirteen patients were treated with both the oral and intravenous preparations of 4-demethoxydaunorubicin (DMDR). The drug was well tolerated in both forms. Neutropenia was the dose-limiting side-effect. Approximately 30{\%} of the compound was absorbed when given orally. The maximum tolerated dose was 12.5 mg/m2 intravenously or 50 mg/m2 (10 mg/m2 q d × 5) orally, given every 21-28 days.",
author = "Kavanagh, {John J.} and Yeung, {Katherine Y.} and Niramol Savaraj and Krakoff, {Irwin H.}",
year = "1985",
month = "1",
day = "1",
doi = "10.1016/0277-5379(85)90013-6",
language = "English",
volume = "21",
pages = "1187--1189",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "10",

}

TY - JOUR

T1 - Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin

AU - Kavanagh, John J.

AU - Yeung, Katherine Y.

AU - Savaraj, Niramol

AU - Krakoff, Irwin H.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Thirteen patients were treated with both the oral and intravenous preparations of 4-demethoxydaunorubicin (DMDR). The drug was well tolerated in both forms. Neutropenia was the dose-limiting side-effect. Approximately 30% of the compound was absorbed when given orally. The maximum tolerated dose was 12.5 mg/m2 intravenously or 50 mg/m2 (10 mg/m2 q d × 5) orally, given every 21-28 days.

AB - Thirteen patients were treated with both the oral and intravenous preparations of 4-demethoxydaunorubicin (DMDR). The drug was well tolerated in both forms. Neutropenia was the dose-limiting side-effect. Approximately 30% of the compound was absorbed when given orally. The maximum tolerated dose was 12.5 mg/m2 intravenously or 50 mg/m2 (10 mg/m2 q d × 5) orally, given every 21-28 days.

UR - http://www.scopus.com/inward/record.url?scp=0022358778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022358778&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(85)90013-6

DO - 10.1016/0277-5379(85)90013-6

M3 - Article

C2 - 3865774

AN - SCOPUS:0022358778

VL - 21

SP - 1187

EP - 1189

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 10

ER -